Insight Molecular Diagnostics (IMDX) Capital Expenditures Growth (1y) (2016 - 2026)
Insight Molecular Diagnostics (IMDX) Capital Expenditures Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 53.06% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 8.47% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | -27.73% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | -33.33% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 31.13% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 1.48% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 33.33% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 16.40% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 27.78% |
| 10 | Insight Molecular Diagnostics | 172.42 Mn | 143.49 Mn | 15,000.00 | 99.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.67% |
| Dec 31, 2025 | 591.12% |
| Sep 30, 2025 | 1,106.90% |
| Jun 30, 2025 | 82.72% |
| Mar 31, 2025 | 1,179.17% |
| Dec 31, 2024 | -18.94% |
| Sep 30, 2024 | 115.43% |
| Dec 31, 2023 | -67.08% |
| Sep 30, 2023 | -165.66% |
| Dec 31, 2022 | 100.00% |
| Sep 30, 2022 | 118.02% |
| Jun 30, 2022 | 83.28% |
| Mar 31, 2022 | 85.39% |
| Dec 31, 2021 | 141.57% |
| Sep 30, 2021 | -25.10% |
| Jun 30, 2021 | 24.24% |
| Mar 31, 2021 | 1,813.64% |
| Dec 31, 2020 | -81.56% |
| Jun 30, 2020 | 4,363.64% |
| Mar 31, 2020 | 528.57% |